Brought to you by:
New VOYAGER PAD analysis confirms consistent benefit of low-dose rivaroxaban plus aspirin following lower extremity revascularization
Data from a new prespecified analysis of the phase III VOYAGER PAD clinical trial show that low-dose rivaroxaban plus aspirin resulted in a 33% reduction in acute limb ischemia and a 15% reduction in major adverse limb and cardiovascular events,…
Janssen applies to FDA for new indication to expand use of rivaroxaban in PAD patients
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the Food and Drug Administration (FDA) for a new indication to expand the use of Xarelto (rivaroxaban) in patients with…